Instil Bio (TIL) Stock Forecast, Price Target & Predictions
TIL Stock Forecast
Instil Bio stock forecast is as follows: an average price target of $78.25 (represents a 98.30% upside from TIL’s last price of $39.46) and a rating consensus of 'Hold', based on 3 wall street analysts offering a 1-year stock forecast.
TIL Price Target
TIL Analyst Ratings
Instil Bio Price Target by Analyst
Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
---|---|---|---|---|---|---|
Sep 16, 2024 | Jack Allen | Robert W. Baird | $180.00 | $65.58 | 174.47% | 356.16% |
Sep 16, 2024 | Mitchell Kapoor | H.C. Wainwright | $120.00 | $84.52 | 41.98% | 204.11% |
Sep 12, 2024 | Mitchell Kapoor | H.C. Wainwright | $40.00 | $39.19 | 2.07% | 1.37% |
Apr 12, 2024 | Kelly Shi | Jefferies | $11.00 | $11.06 | -0.54% | -72.12% |
Dec 12, 2022 | - | Morgan Stanley | $2.00 | $0.84 | 138.32% | -94.93% |
Jun 05, 2022 | Vikram Purohit | Morgan Stanley | $9.00 | $6.01 | 49.75% | -77.19% |
Instil Bio Price Target by Period
1M | 3M | 12M | |
---|---|---|---|
# Anlaysts | - | 3 | 4 |
Avg Price Target | - | $113.33 | $87.75 |
Last Closing Price | $39.46 | $39.46 | $39.46 |
Upside/Downside | -100.00% | 187.20% | 122.38% |
Analyst Ratings Upgrades/Downgrades
Date | Company | Previous Rating | New Rating | Rating Change |
---|---|---|---|---|
Sep 16, 2024 | H.C. Wainwright | Buy | Buy | Hold |
Aug 23, 2024 | H.C. Wainwright | Buy | Buy | Hold |
Apr 12, 2024 | Jefferies | - | Hold | Downgrade |
Dec 12, 2022 | Morgan Stanley | Equal-Weight | Equal-Weight | Hold |
Instil Bio Financial Forecast
Instil Bio Revenue Forecast
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Dec 22 | |
---|---|---|---|---|---|---|---|---|
Revenue | - | - | - | - | - | - | - | - |
Avg Forecast | - | - | - | - | - | - | - | $1.00M |
High Forecast | - | - | - | - | - | - | - | $1.00M |
Low Forecast | - | - | - | - | - | - | - | $1.00M |
# Analysts | - | - | - | - | - | - | - | 1 |
Surprise % | - | - | - | - | - | - | - | - |
Instil Bio EBITDA Forecast
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Dec 22 | |
---|---|---|---|---|---|---|---|---|
# Analysts | - | - | - | - | - | - | - | 1 |
EBITDA | - | - | - | - | - | - | - | $-30.54M |
Avg Forecast | - | - | - | - | - | - | - | $600.00K |
High Forecast | - | - | - | - | - | - | - | $600.00K |
Low Forecast | - | - | - | - | - | - | - | $600.00K |
Surprise % | - | - | - | - | - | - | - | -50.90% |
Instil Bio Net Income Forecast
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Dec 22 | |
---|---|---|---|---|---|---|---|---|
# Analysts | - | - | - | - | - | - | - | 1 |
Net Income | - | - | - | - | - | - | - | $-53.84M |
Avg Forecast | $-28.19M | $-24.68M | $-21.76M | $-19.12M | $-12.86M | $-13.64M | $-19.38M | $-53.77M |
High Forecast | $-28.19M | $-24.68M | $-21.76M | $-19.12M | $-12.86M | $-13.64M | $-19.38M | $-53.77M |
Low Forecast | $-28.19M | $-24.68M | $-21.76M | $-19.12M | $-12.86M | $-13.64M | $-19.38M | $-53.77M |
Surprise % | - | - | - | - | - | - | - | 1.00% |
Instil Bio SG&A Forecast
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Dec 22 | |
---|---|---|---|---|---|---|---|---|
# Analysts | - | - | - | - | - | - | - | 1 |
SG&A | - | - | - | - | - | - | - | $12.91M |
Avg Forecast | - | - | - | - | - | - | - | $21.64M |
High Forecast | - | - | - | - | - | - | - | $21.64M |
Low Forecast | - | - | - | - | - | - | - | $21.64M |
Surprise % | - | - | - | - | - | - | - | 0.60% |
Instil Bio EPS Forecast
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Dec 22 | |
---|---|---|---|---|---|---|---|---|
# Analysts | - | - | - | - | - | - | - | 1 |
EPS | - | - | - | - | - | - | - | $-0.41 |
Avg Forecast | $-4.33 | $-3.79 | $-3.35 | $-2.94 | $-1.98 | $-2.10 | $-2.98 | $-8.27 |
High Forecast | $-4.33 | $-3.79 | $-3.35 | $-2.94 | $-1.98 | $-2.10 | $-2.98 | $-8.27 |
Low Forecast | $-4.33 | $-3.79 | $-3.35 | $-2.94 | $-1.98 | $-2.10 | $-2.98 | $-8.27 |
Surprise % | - | - | - | - | - | - | - | 0.05% |
Instil Bio Peer Comparison by Price Target
Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
---|---|---|---|---|---|
SPRO | Spero Therapeutics | $1.29 | $10.00 | 675.19% | Buy |
CTMX | CytomX Therapeutics | $1.16 | $5.77 | 397.41% | Buy |
NUVB | Nuvation Bio | $2.43 | $6.75 | 177.78% | Buy |
NXTC | NextCure | $1.45 | $3.00 | 106.90% | Buy |
ACHL | Achilles Therapeutics | $0.99 | $2.00 | 102.02% | Buy |
TIL | Instil Bio | $39.46 | $78.25 | 98.30% | Hold |
ASMB | Assembly Biosciences | $18.10 | $35.50 | 96.13% | Buy |
TIL Forecast FAQ
Is Instil Bio a good buy?
No, according to 3 Wall Street analysts, Instil Bio (TIL) is considered a 'Hold'. The rating consensus is based on 0 'Strong Buy' and 1 'Buy' recommendations, accounting for 33.33% of TIL's total ratings.
What is TIL's price target?
Instil Bio (TIL) average price target is $78.25 with a range of $2 to $180, implying a 98.30% from its last price of $39.46. The data is based on 3 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Instil Bio stock go up soon?
According to Wall Street analysts' prediction for TIL stock, the company can go up by 98.30% (from the last price of $39.46 to the average price target of $78.25), up by 356.16% based on the highest stock price target, and down by -94.93% based on the lowest stock price target.
Can Instil Bio stock reach $60?
TIL's average twelve months analyst stock price target of $78.25 supports the claim that Instil Bio can reach $60 in the near future.
What are Instil Bio's analysts' financial forecasts?
Instil Bio's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-45.874M (high $-45.874M, low $-45.874M), average SG&A $0 (high $0, low $0), and average EPS is $-7.053 (high $-7.053, low $-7.053). TIL's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-93.754M (high $-93.754M, low $-93.754M), average SG&A $0 (high $0, low $0), and average EPS is $-14.415 (high $-14.415, low $-14.415).